摘要目的 探讨不同种类β内酰胺类抗生素对肺部疾病患者血清半乳甘露聚糖检测假阳性率的影响. 方法 选择因肺部疾病而入住呼吸内科并接受不同β内酰胺类抗生素治疗的非侵袭性曲霉菌病(IPA)患者77例作为试验组,以41例未使用任何抗生素的非IPA患者为对照组,两组均行血清半乳甘露聚糖检测,比较两组半乳甘露聚糖的假阳性率. 结果 哌拉西林/他唑巴坦组患者半乳甘露聚糖的假阳性率为30.8％(8/26),头孢哌酮/舒巴坦组患者假阳性率为27.8％(5/18).使用β内酰胺类抗生素组发生半乳甘露聚糖假阳性率显著高于对照组[24.7％(19/77)比7.3％(3/41),x2=5.315,P=0.025].以半乳甘露聚糖假阳性为因变量,是否应用β内酰胺类抗生素为自变量行单因素Logistic回归分析,结果显示,应用β内酰胺类抗生素组发生半乳甘露聚糖假阳性率的几率是对照组的4.149倍(OR=4.149,P=0.030). 结论 使用β内酰胺类抗生素可能增加血清半乳甘露聚糖检测假阳性率,临床医生在解读血清半乳甘露聚糖检测结果时需注意排除抗生素的影响.

abstractsObjective To investigate the effect of β-lactam antibiotics on the false positive rate of the serum Aspergillus galactomannan (GM) assay in patients with lung diseases.Methods We selectively recruited 77 lung disease patients who did not meet the diagnostic criteria of invasive pulmonary Aspergillosis (IPA) and received different β-lactam antibiotics,while 41 patients without IPA who did not receive any antibiotic treatment were recruited as the control group.Serum samples for GM detection were collected from all participants.The rate of false-positive Aspergillus galactomannan was compared between the two groups.Results False-positive serum results were found in patients who received piperacillin-tazobactam (30.8％ or 8/26) and cefoperazone sulbactamand (27.8％ or 5/18).The rate of false-positive Aspergillus galactomannan in patients who receive β-lactam antibiotics were significantly higher than that in the control group (24.7％ or 19/77vs.7.3％ or 3/41,x2 =5.315,P=0.025).Taking false-positive serum Aspergillus galactomannan as the dependent variable and β-lactam antibiotic treatment as the independent variable,univariate logistic regression analysis showed that the rate of false-positive Aspergillus galactomannan in patients who received β-lactam antibiotics were 4.149 times more than that in the control group (OR=4.149,P=0.030).Conclusions The administration of β-lactam antibiotics may increase the occurrence of false-positive serum Aspergillus galactomannan,and physicians should be aware of this possible interference.